In a major win for Indian pharma, Aurobindo Pharma has received approval from the UK’s MHRA for its biosimilar drug Zefylti, a version of filgrastim. This drug is used to treat neutropenia — a condition where chemotherapy patients lose too many white blood cells, making them vulnerable to infections.
Why This Approval Matters
Zefylti is a biosimilar, meaning it mimics a well-known biologic drug (in this case, Neupogen by Amgen) but at a more affordable price. Getting approved in a regulated market like the UK is a big deal — it signals quality, opens doors across Europe, and boosts Aurobindo’s credibility.
What’s the Market Like?
The global biosimilar market is booming. With many blockbuster biologics going off-patent, there’s a rush to capture this space. Biosimilars like Zefylti are in demand for being:
For Aurobindo, this means more revenue from regulated markets — and less dependence on the low-margin US generics space.
What’s Next for Aurobindo?
This approval is part of a larger game plan. The company is building a biosimilar portfolio that includes drugs for oncology, immunology, and rare diseases. Zefylti is the first in a series, and more are expected to follow in FY26–FY27.
It also helps Aurobindo transition from being a generic drug giant to a global player in complex, high-value medicines — exactly the kind of pivot that Indian pharma needs right now.
For more information, visit https://www.indiratrade.com/